Compare OCG & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCG | GRI |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.3M |
| IPO Year | 2019 | 2020 |
| Metric | OCG | GRI |
|---|---|---|
| Price | $0.85 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 291.0K | 69.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.01 | $0.18 |
| 52 Week High | $19.29 | $6.70 |
| Indicator | OCG | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 57.13 |
| Support Level | $0.57 | $2.15 |
| Resistance Level | $1.09 | $2.74 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 97.62 | 69.68 |
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.